undamentalytics Newsletter
Sign in

Whitehawk Therapeutics, Inc. income statement

In fiscal 2025, Whitehawk Therapeutics, Inc. reported revenue of $7.1m, down 72.5% on the year before, operating income of −$114m (a -1601.1% margin) and net income of −$20.6m, or −$0.33 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue200141415242670
Cost of revenue———013310
Gross profit———1414222360
Research and development181315203349519163
Selling, general and administrative———194045373023
General and administrative13102——————
Operating income−11−24−3−111−63−72−67−114−86
Interest expense——110000—
Provision for credit losses——00—————
Income before tax——−3−110−61−66−64−21—
Income tax——0000000
Net income−10−23−3−110−61−66−64−21−80
Diluted EPS−$0.31−$8.55−$1.76−$12.41−$2.69−$2.44−$2.36−$0.33−$1.10
Diluted shares (average)2m3m3m9m23m27m27m62m73m
EBITDA−11−24−3−111−63−72−67−114−86

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Whitehawk Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Whitehawk Therapeutics, Inc.